The Latest Cardiac and Vascular News
WASHINGTON, Nov. 26, 2024 /PRNewswire/ — Patients with heart failure (HF) suffer from compromised quality of life, high mortality, and complex medical decision-making. Palliative care is an essential part of a comprehensive HF care plan. Integration of Palliative Care into Heart Failure…
– New digital health solution for heart failure management puts patients at the center of their care by providing ability for at-home disease monitoring – TOKYO, Sept. 18, 2024 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced…
WASHINGTON, Sept. 10, 2024 /PRNewswire/ — Novel device-based therapies may overcome limitations of pharmacologic therapies for some patients living with heart failure (HF), indicating that a synergistic approach between the two therapies is ideal for implementation of guideline directed…
May 13, 2024 09:28 AM Eastern Daylight Time CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that a new analysis of data from the remedē® System Pivotal Trial suggests favorable outcomes for […]
TOKYO–(BUSINESS WIRE)–Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure, today announced that the case reports of two patients in the Phase 1/2 clinical trial (LAPiS Study) of HS-001 in combination with coronary artery bypass grafting […]
LONDON, July 30, 2018 /PRNewswire/ — Stem Cell Therapies in CVMDSummaryRegenerative medicine could potentially cure diseases and may replace palliative treatments for chronic diseases.Stem cells in particular have been studied for their regenerative properties: their potential to repair or replace damaged or diseased […]
NEW YORK and MELBOURNE, Australia, Dec. 21, 2017 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the United States Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for its novel mesenchymal precursor cell (MPC) therapy […]
ORANGEBURG, New York and STUTTGART, Germany, December 18, 2017 /PRNewswire/ — The China Food and Drug Administration (CFDA) has approved Impulse Dynamics’ Optimizer® system for treatment of chronic heart failure. The announcement was made on December 12, 2017 by Impulse Dynamics’ CEO, Dr. Simos Kedikoglou. “This is a […]
HOUSTON–(BUSINESS WIRE)–October 26, 2017– CorInnova Inc., an emerging medical device company developing novel technology for the treatment of Heart Failure, announced today three milestone events: (1) the Company has received notice of allowance of a seminal patent to protect its intellectual […]
DUBLIN – September 27, 2017 – Medtronic plc (NYSE: MDT) has received U.S. Food and Drug Administration (FDA) approval for its HeartWare(TM) HVAD(TM) System as a destination therapy for patients with advanced heart failure who are not candidates for heart transplants. […]
